* The purpose of this podcast is to educate and to inform. The content of this podcast does not constitute medical advice and it is not intended to function as a substitute for a healthcare practitioner’s judgement, patient care or treatment. The views expressed by contributors are those of the speakers. BMJ does not endorse any views or recommendations discussed or expressed on this podcast. Listeners should also be aware that professionals in the field may have different opinions. By listening to this podcast, listeners agree not to use its content as the basis for their own medical treatment or for the medical treatment of others.
DTB Podcast
For 50 years, Drug and Therapeutics Bulletin (DTB) has provided rigorous and independent evaluations of, and practical advice on, individual treatments and the overall management of disease for doctors, pharmacists and other healthcare professionals. DTB has always been wholly independent of the pharmaceutical industry, Government and regulatory authorities. DTB is also free of advertising and other forms of commercial sponsorship. Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page - https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309.
Listen on:
Episodes
Monday Jul 25, 2022
Monday Jul 25, 2022
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the August 2022 issue of DTB. They discuss progress in reducing use of psychotropic medications in adults and children with a learning disability, autism or both (https://dtb.bmj.com/content/60/8/114). They also provide an overview of a study that assessed the effect of deprescribing antihypertensive medication in older people (https://dtb.bmj.com/content/60/8/118) and talk about a national safety alert relating to amiodarone (https://dtb.bmj.com/content/60/8/116). They end the podcast with a discussion on the evidence for the lipid-lowering drug bempedoic acid and its effect on reducing low-density lipoprotein-cholesterol and the lack of evidence on clinical outcomes (https://dtb.bmj.com/content/60/8/120).
The contact address for the DTB team is dtb@bmj.com.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Tuesday Jun 28, 2022
Tuesday Jun 28, 2022
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the July 2022 issue of DTB. They discuss the proposed reclassification of estradiol vaginal tablets from Prescription Only Medicine to a Pharmacy medicine (https://dtb.bmj.com/content/60/7/98) and review a study that assessed pharmaceutical industry funding of All Party Parliamentary Groups (https://dtb.bmj.com/content/60/7/100). They talk about the evidence for the lipid-lowering drug inclisiran and its effect on reducing low-density lipoprotein-cholesterol and the lack of evidence on clinical outcomes (https://dtb.bmj.com/content/60/7/102). The editors also highlight a case report of acute lung toxicity caused by nitrofurantoin (https://dtb.bmj.com/content/60/7/108).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Thursday May 26, 2022
Thursday May 26, 2022
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the June 2022 issue of DTB. They discuss the impact that the cessation of spirometry services in primary care has had on diagnosing obstructive lung disease (https://dtb.bmj.com/content/60/6/82). They highlight two separate patient safety incident reports from the Healthcare Safety Investigation Branch - confusion over the prescribed dose of oral morphine solution and the harm caused by a standard therapeutic dose of paracetamol in a frail older person (https://dtb.bmj.com/content/60/6/84). The editors also talk about an article on serotonin syndrome (https://dtb.bmj.com/content/60/6/88).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Read the June issue: https://dtb.bmj.com/content/60/6
Tuesday Apr 26, 2022
Tuesday Apr 26, 2022
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the May 2022 issue of DTB. They talk about drug bulletins across the world and the role of the International Society of Drug Bulletins in supporting bulletins and ensuring that they are intellectually and financially independent (https://dtb.bmj.com/content/60/5/66). They review a study that assessed the use of mirtazapine for treating agitation in people with dementia (https://dtb.bmj.com/content/60/5/68). The editors also discuss the evidence behind two new oral antivirals that have been licensed for the treatment of covid-19 (https://dtb.bmj.com/content/60/5/73).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Tuesday Mar 22, 2022
Tuesday Mar 22, 2022
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the April 2022 issue of DTB. They talk about DTB's 60th anniversary, the importance of independent scrutiny of new medicines and the need to question how medicines are licensed and used (https://dtb.bmj.com/content/60/4/50). They highlight the benefits of a comprehensive national register of conflicts of interest and discuss a study that compared a quadpill containing low doses of four antihypertensive agents with a standard dose of irbesartan (https://dtb.bmj.com/content/60/4/56). They also review a study that assessed clinicians' awareness of the harms from long-term use of nitrofurantoin (https://dtb.bmj.com/content/60/4/59) and provide an overview of an article on managing hypertension in pregnancy (https://dtb.bmj.com/content/60/4/60). The editors also look back at the very first issue of DTB that was published on 20th April 1962 (https://dtb.bmj.com/content/s1-1/1).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Tuesday Feb 22, 2022
Tuesday Feb 22, 2022
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the March 2022 issue of DTB. They talk about paracetamol and its effect on blood pressure and discuss progress on moving to inhalers that have less of an impact on the environment (https://dtb.bmj.com/content/60/3/34). The editors review a study that examined harms from medicines (https://dtb.bmj.com/content/60/3/37) and discuss the use of naldemedine in the management of opioid-induced constipation (https://dtb.bmj.com/content/60/3/39).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Tuesday Jan 25, 2022
Tuesday Jan 25, 2022
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the February 2022 issue of DTB. They talk about some of the details from a national report on overprescribing and discuss its implications (https://dtb.bmj.com/content/60/2/18). The editors review a study that highlighted overprescribing of short-acting beta agonists in people with asthma (https://dtb.bmj.com/content/60/2/21). They also discuss an article on prescribing for women of childbearing age who have inflammatory bowel disease and managing medicines during pregnancy (https://dtb.bmj.com/content/60/2/24).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Saturday Dec 18, 2021
Saturday Dec 18, 2021
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the January 2022 issue of DTB. They discuss the UK Medicines and Healthcare products Regulatory Agency's decision to license the oral antiviral drug molnupiravir (Lagevrio) and the paucity of publicly available clinical trial data - https://dtb.bmj.com/content/60/1/2. The editors talk about a study that highlighted potentially inappropriate prescribing in middle-aged adults - https://dtb.bmj.com/content/60/1/6. They also review an article on some of the challenges facing people when they try to stop taking antidepressants - https://dtb.bmj.com/content/60/1/7.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Monday Nov 22, 2021
Monday Nov 22, 2021
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the December issue of DTB. They discuss a recently published national report on overprescribing of medicines. The editors talk about a study that assessed the accuracy of home blood pressure monitors (https://dtb.bmj.com/content/59/12/179) and highlight a safety alert on topical steroid withdrawal reactions (https://dtb.bmj.com/content/59/12/184). They also review an article on the US Food and Drug Administration's decision to license bremelanotide and flibanserin for 'hypoactive sexual desire disorder’ in women (https://dtb.bmj.com/content/59/12/185).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.
Sunday Oct 24, 2021
Sunday Oct 24, 2021
In this podcast, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) provide an overview of the November issue of DTB. They discuss a French initiative that identifies a range of drugs that should not be prescribed (https://dtb.bmj.com/content/59/11/162) and talk about the difficulty of assessing whether patients' penicillin allergy records are correct (https://dtb.bmj.com/content/59/11/163). They also review an article on the use of romosozumab for osteoporosis (https://dtb.bmj.com/content/59/11/169). They begin by highlighting DTB's blog for World Evidence-Based Healthcare Day (https://worldebhcday.org/) on the role of independent drug bulletins during an info-demic.
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). Thank you for listening.